PFE Stock Recent News
PFE LATEST HEADLINES
Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.
In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.
Companies with attractive valuations, strong competitive advantages, and sustainable dividend growth can help investors steadily increase wealth while reducing risk. The selection process of my top 10 high dividend yield companies for April 2025 involves analyzing financial ratios, competitive advantages, valuations, and ensuring diversification across industries and countries. The 10 selected companies offer investors an Average Dividend Yield [FWD] of 5.30% and a 5-Year Average Dividend Growth Rate [CAGR] of 8.33%, allowing investors to combine income and growth.
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Institutional Shareholder Services is recommending Pfizer's investors to reject a management proposal on annual compensation for CEO Albert Bourla and other executives, the proxy adviser said on Wednesday.
The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.
The “buy the dip” strategy worked flawlessly for over two years.
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in sentiment toward an entire sector.
Many investor eyes were on the pharmaceutical industry on Tuesday, and not necessarily for the right reasons. The Trump administration's promised tariffs were set to go into effect the following day, and the sector has been mentioned as a key area of focus for these.